A subscription to JoVE is required to view this content. Sign in or start your free trial.
We describe a method for generating and amplifying genetically modified respiratory syncytial viruses (RSVs) and an optimized plaque assay for RSVs. We illustrate this protocol by creating two recombinant viruses that respectively allow quantification of RSV replication and live analysis of RSV inclusion bodies and inclusion bodies-associated granules dynamics.
The use of recombinant viruses has become crucial in basic or applied virology. Reverse genetics has been proven to be an extremely powerful technology, both to decipher viral replication mechanisms and to study antivirals or provide development platform for vaccines. The construction and manipulation of a reverse genetic system for a negative-strand RNA virus such as a respiratory syncytial virus (RSV), however, remains delicate and requires special know-how. The RSV genome is a single-strand, negative-sense RNA of about 15 kb that serves as a template for both viral RNA replication and transcription. Our reverse genetics system uses a cDNA copy of the human RSV long strain genome (HRSV). This cDNA, as well as cDNAs encoding viral proteins of the polymerase complex (L, P, N, and M2-1), are placed in individual expression vectors under T7 polymerase control sequences. The transfection of these elements in BSR-T7/5 cells, which stably express T7 polymerase, allows the cytoplasmic replication and transcription of the recombinant RSV, giving rise to genetically modified virions. A new RSV, which is present at the cell surface and in the culture supernatant of BSRT7/5, is gathered to infect human HEp-2 cells for viral amplification. Two or three rounds of amplification are needed to obtain viral stocks containing 1 x 106 to 1 x 107 plaque-forming units (PFU)/mL. Methods for the optimal harvesting, freezing, and titration of viral stocks are described here in detail. We illustrate the protocol presented here by creating two recombinant viruses respectively expressing free green fluorescent protein (GFP) (RSV-GFP) or viral M2-1 fused to GFP (RSV-M2-1-GFP). We show how to use RSV-GFP to quantify RSV replication and the RSV-M2-1-GFP to visualize viral structures, as well as viral protein dynamics in live cells, by using video microscopy techniques.
Human RSV is the leading cause of hospitalization for acute respiratory tract infection in infants worldwide1. In addition, RSV is associated with a substantial disease burden in adults comparable to influenza, with most of the hospitalization and mortality burden in the elderly2. There are no vaccines or specific antivirals available yet against RSV, but promising new drugs are in development3,4. The complexity and the heaviness of the techniques of quantification of RSV multiplication impede the search for antivirals or vaccines despite current considerable efforts. The quantification of RSV multiplication in vitro is generally based on laborious, time-consuming, and expensive methods, which consist mostly in the analysis of the cytopathic effect by microscopy, immunostaining, plaque reduction assays, quantitative reverse transcriptase (qRT)-polymerase chain reaction (PCR), and enzyme-linked immunosorbent assay tests. Viruses with modified genomes and expressing reporter genes, such as those coding for the GFP, are more suitable for such screenings. Coupled to the use of automated plate readers, reporter gene-carrying recombinant viruses can make these assays more suitable for standardization and high-throughput purposes.
RSV is an enveloped, nonsegmented negative-sense RNA virus that belongs to the Orthopneumovirus genus of the Pneumoviridae family, order Mononegavirales5. The RSV genome is a single-strand, negative-sense RNA of about 15 kb, which contains a noncoding region at the 3' and 5' extremities called Leader and Trailer and 10 transcriptional units encoding 11 proteins. The genes are ordered as follows: 3'-NS1, NS2, N, P, M, SH, G, F, M2 (encoding for M2-1 and M2-2 proteins) and L-5'. The genomic RNA is tightly packaged by the nucleoprotein N. Using the encapsidated genomic RNA as a template, viral RNA-dependent RNA polymerase (RdRp) will ensure transcription and replication of the viral RNA. Viral RdRp is composed of the large protein L which carries the nucleotide polymerase activity per se, its mandatory cofactor the phosphoprotein P and the M2-1 protein which functions as a viral transcription factor6. In infected cells, RSV induces the formation of cytoplasmic inclusions called inclusion bodies (IBs). Morphologically similar cytoplasmic inclusions have been observed for several Mononegavirales7,8,9,10. Recent studies on rabies virus, vesicular stomatitis virus (VSV), Ebola virus, and RSV showed that viral RNA synthesis occurs in IBs, which can thus be regarded as viral factories8,9,11,12. The virus factories concentrate the RNA and viral proteins required for viral RNA synthesis and also contain cellular proteins13,14,15,16,17. IBs exhibit a functional subcompartment called IB-associated granules (IBAGs), which concentrate the newly synthetized nascent viral mRNA together with the M2-1 protein. The genomic RNA and the L, P, and N are not detected in IBAGs. IBAGs are small dynamic spherical structures inside IBs that exhibit the properties of liquid organelles12. Despite the central role of IBs in viral multiplication, very little is known about the nature, internal structure, formation, and operation of these viral factories.
The expression of the genome of a poliovirus from a cDNA enabled the production of the first infectious viral clone in 198118. For single-stranded negative RNA viruses, it was not until 1994 that the production of a first rabies virus following transfection of plasmids into cells19 took place. The first plasmid-based reverse genetic system for RSV was published in 199520. Reverse genetics have led to major advances in the field of virology. The possibility of introducing specific modifications into the viral genome has provided critical insights into the replication and pathogenesis of RNA viruses. This technology has also greatly facilitated the development of vaccines by allowing specific attenuation through targeted series of modifications. Genome modifications allowing a rapid quantification of viral multiplication greatly improved the antiviral screening and study of their mode of action.
Although previously described, obtaining genetically modified RSVs remains delicate. Here, we detail a protocol to create two types of recombinant HRSV, respectively expressing RSV-GFP or RSV-M2-1-GFP. In this protocol, we describe the transfection conditions needed to rescue the new recombinant viruses, as well as their amplification to obtain viral stocks with high titer, suitable for reproducible experimentations. The construction of the reverse genetics' vectors per se is not described here. We do describe methods for the optimal harvesting and freezing of viral stocks. The most accurate method to quantify viral infectious particles remains plaque assay. Cells are infected with serial dilutions of the analyzed suspension and incubated with an overlay that prohibits the diffusion of free viral particles in the supernatant. In such conditions, the virus will only infect contiguous cells forming a "plaque" for each initial infectious particle. In the conventional RSV titration assay, plaques are revealed by immunostaining and counted under microscopic observation. This method is expensive and time-consuming. Here we described a very simple protocol for an RSV plaque assay using microcrystalline cellulose overlay that enables the formation of plaques visible to the naked eye. We show how RSV-GFP can be used to measure RSV replication and, thus, to quantify the impact of antivirals. Combining reverse genetics and live imaging technology, we demonstrate how RSV-M2-1-GFP allows scientists to visualize M2-1 in live cells and to follow the dynamics of intracellular viral structures, such as IBs.
1. Material Preparation
2. Rescue and First Passage of Recombinant Virus
NOTE: Perform all the following steps in a sterile environment, using a class II safety cabinet.
3. Amplification of the Rescued Viruses
NOTE: The following protocol describes the amplification of the rescued viruses in a 75 cm2 flask. Adapt the flask size to the volume needed and the required multiplicity of infection (MOI). Table 1 indicates volumes for different flasks. Perform all the following steps in a sterile environment in a class II safety cabinet.
4. Plaque Titration Assay
5. The Use of HRSV-GFP Recombinant Virus to Monitor Viral Replication in Cells Treated with Small Interfering RNA or Antivirals
NOTE: Perform all steps except 5.1 and 5.2.5 in a sterile environment using a class II safety cabinet.
6. Characterization of M2-1 Localization In Vivo with the RSV-M2-1-GFP Recombinant Virus
NOTE: Perform steps 6.1 and 6.2 in a sterile environment, using a class II safety cabinet.
In this work, we described a detailed protocol to produce recombinant RSV viruses expressing a fluorescent protein (Figure 2). In pRSV-GFP, the GFP gene was introduced between the P and M genes, as described for the Cherry gene in previously published work21. In the pRSV-M2-1-GFP, the M2 gene was left untouched and an additional gene coding for M2-1-GFP was inserted between SH and G genes12. The first step, corr...
Here we present a method of rescue of recombinant RSVs from five plasmids, and their amplification. The ability to manipulate the genome of viruses has revolutionized virology research to test mutations and express an additional gene or a tagged viral protein. The RSV we have described and used as an example in this article is a virus expressing a reporter gene, the RSV-GFP (unpublished), and expresses an M2-1 protein fused to a GFP tag12. RSV rescue is challenging and requires practice. The trans...
The authors have nothing to disclose.
The authors thank Dr. Qin Yu from AstraZeneca R&D Boston, MA, USA, for providing the AZD4316 drug. The authors are grateful to the Cymages platform for access to the ScanR Olympus microscope, which was supported by grants from the region Ile-de-France (DIM ONE HEALTH). The authors acknowledge support from the INSERM and the Versailles Saint-Quentin University.
Name | Company | Catalog Number | Comments |
35mm µ dish for live cell imaging | Ibidi | 81156 | |
A549 | ATCC | ATCC CCL-185 | |
Avicel RC-591 | FMC BioPolymer | Avicel RC-591 | Technical and other information on Avicels is available at http://www.fmcbiopolymer.com. Store at room temperature. Protocol in step 4 is optimized for this reagent. |
BSRT7/5 | not commercially available | See ref 22. Buchholz et al, 1999 | |
Crystal violet solution | Sigma | HT90132 | |
Fluorescence microscope for observations | Olympus | IX73 Olympus microscope | |
Fluorescence microscope for videomicroscopy | Olympus | ScanR Olympus microscope | |
HEp-2 | ATCC | ATCC CCL-23 | |
HEPES ≥99.5% | Sigma | H3375 | |
L-Glutamine (200 mM) | ThermoFisher Scientific | 25030024 | |
LIPOFECTAMINE 2000 REAGENT | ThermoFisher Scientific | 11668019 | Protocol in step 2.3. is optimized for this reagent. |
MEM (10X), no glutamine | ThermoFisher Scientific | 11430030 | |
MEM, GlutaMAX Supplement | ThermoFisher Scientific | 41090-028 | |
MgSO4 ReagentPlus, ≥99.5% | Sigma | M7506 | |
Opti-MEM I Reduced Serum Medium | ThermoFisher Scientific | 51985-026 | |
Paraformaldehyde Aqueous Solution, 32%, EM Grade | Electron Microscopy Sciences | 15714 | |
Penicillin-Streptomycin (10,000 U/mL) | ThermoFisher Scientific | 15140122 | |
Plasmids | not commercially available | see ref 21. Rameix-Welti et al, 2014 | |
See Saw Rocker | VWR | 444-0341 | |
Si RNA GAPDH | Dharmacon | ON-TARGETplus siRNA D-001810-10-05 | SMARTpool and 3 of 4 individual siRNAs designed by Dharmacon. |
Si RNA IMPDH2 | Dharmacon | ON-TARGETplus siRNA IMPDH2 Pool- Human L-004330-00-0005 | SMARTpool of 4 individual siRNAs designed by Dharmacon. Individual references and sequences J-004330-06: GGAAAGUUGCCCAUUGUAA; J-004330-07: GCACGGCGCUUUGGUGUUC; J-004330-08: AAGGGUCAAUCCACAAAUU; J-004330-09: GGUAUGGGUUCUCUCGAUG; |
Si RNA RSV N | Dharmacon | ON-TARGETplus custom siRNA | UUCAGAAGAACUAGAGGCUAU and UUUCAUAAAUUCACUGGGUUA |
SiRNA NT | Dharmacon | ON-TARGETplus Non-targeting Pool | |
SiRNA transfection reagent | Dharmacon | DharmaFECT 1 Ref: T-2001-03 | Protocol in steps 5.1.and 5.1.2 are optimized for this reagent. |
Sodium Bicarbonate 7.5% solution | ThermoFisher Scientific | 25080094 | |
Spectrofluorometer | Tecan | Tecan infinite M200PRO |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved